JP2024531799A5 - - Google Patents
Info
- Publication number
- JP2024531799A5 JP2024531799A5 JP2024517163A JP2024517163A JP2024531799A5 JP 2024531799 A5 JP2024531799 A5 JP 2024531799A5 JP 2024517163 A JP2024517163 A JP 2024517163A JP 2024517163 A JP2024517163 A JP 2024517163A JP 2024531799 A5 JP2024531799 A5 JP 2024531799A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163246547P | 2021-09-21 | 2021-09-21 | |
| US63/246,547 | 2021-09-21 | ||
| PCT/US2022/076757 WO2023049731A2 (en) | 2021-09-21 | 2022-09-21 | Methods of treating myelodysplastic syndromes with decitabine and cedazuridine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024531799A JP2024531799A (ja) | 2024-08-29 |
| JPWO2023049731A5 JPWO2023049731A5 (https=) | 2025-09-30 |
| JP2024531799A5 true JP2024531799A5 (https=) | 2025-09-30 |
Family
ID=85721229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024517163A Pending JP2024531799A (ja) | 2021-09-21 | 2022-09-21 | 骨髄異形成症候群をデシタビン及びセダズリジンを用いて処置する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250000888A1 (https=) |
| EP (1) | EP4404940A4 (https=) |
| JP (1) | JP2024531799A (https=) |
| KR (1) | KR20240064656A (https=) |
| CN (1) | CN118201622A (https=) |
| AU (1) | AU2022348907A1 (https=) |
| CA (1) | CA3232623A1 (https=) |
| MX (1) | MX2024003537A (https=) |
| TW (1) | TW202327625A (https=) |
| WO (1) | WO2023049731A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4704834A1 (en) * | 2023-05-02 | 2026-03-11 | Taiho Pharmaceutical Co., Ltd. | Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2649997B1 (en) * | 2007-12-10 | 2019-01-23 | Sunesis Pharmaceuticals, Inc. | (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome |
| WO2016085876A1 (en) * | 2014-11-25 | 2016-06-02 | The Broad Institute Inc. | Clonal haematopoiesis |
| US11224610B2 (en) * | 2018-09-19 | 2022-01-18 | Otsuka Pharmaceutical Co., Ltd. | Low dose combination CDA substrate drug/cedazuridine with extended administration |
| JP2023504515A (ja) * | 2019-12-05 | 2023-02-03 | スミトモ ファーマ オンコロジー， インコーポレイテッド | 骨髄異形成症候群の処置のための併用療法 |
| JP2023510393A (ja) * | 2020-01-17 | 2023-03-13 | ノバルティス アーゲー | 骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのｔｉｍ－３阻害剤と低メチル化剤とを含む組合せ |
| PH12022552250A1 (en) * | 2020-02-25 | 2023-11-13 | Otsuka Pharma Co Ltd | Combination decitabine and cedazuridine solid oral dosage forms |
-
2022
- 2022-09-21 WO PCT/US2022/076757 patent/WO2023049731A2/en not_active Ceased
- 2022-09-21 TW TW111135794A patent/TW202327625A/zh unknown
- 2022-09-21 KR KR1020247010215A patent/KR20240064656A/ko active Pending
- 2022-09-21 US US18/693,727 patent/US20250000888A1/en active Pending
- 2022-09-21 CA CA3232623A patent/CA3232623A1/en active Pending
- 2022-09-21 CN CN202280073476.0A patent/CN118201622A/zh active Pending
- 2022-09-21 JP JP2024517163A patent/JP2024531799A/ja active Pending
- 2022-09-21 MX MX2024003537A patent/MX2024003537A/es unknown
- 2022-09-21 AU AU2022348907A patent/AU2022348907A1/en active Pending
- 2022-09-21 EP EP22873816.7A patent/EP4404940A4/en active Pending